Stock comparison
Haemonetics
Vericel
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
VCEL
Vericel
Market cap
$1.77B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | VCEL | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 52D | HAE |
| Benjamin Graham | 85A | 69D | HAE |
| Philip Fisher | 60C | 57C | HAE |
| Peter Lynch | 54C | 45D | HAE |
| Joel Greenblatt | 31F | 44D | VCEL |
| Charlie Munger | 54D | 43D | HAE |
| Terry Smith | 55D | 52D | HAE |
Side-by-side metrics
| Metric | HAE | VCEL |
|---|---|---|
| Market cap | $2.98B | $1.77B |
| P/E (TTM) | 24.8x | 82.5x |
| EV/EBIT | 14.1x | 159.9x |
| ROIC (TTM) | 8.37% | 3.35% |
| Gross margin | 55.74% | 74.84% |
| Net margin | 7.29% | 7.35% |
| Revenue CAGR 5y | 7.65% | 15.32% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 159.9x+91%
- P/E (TTM)24.8xvs 82.5x+70%
- ROIC (TTM)8.37%vs 3.35%+60%
- Market cap$2.98Bvs $1.77B+40%
VCEL leads on
- Debt / Equity0.3xvs 1.5x+83%
- Revenue CAGR 5y15.32%vs 7.65%+50%
- Gross margin74.84%vs 55.74%+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.